Sun States Fund, L.P.Mpm As... Net Worth

The estimated Net Worth of Sun States Fund, L.P.Mpm As... is at least $343 Tausend dollars as of 6 October 2020. Sun As owns over 173,776 units of Oncorus stock worth over $343,359 and over the last 6 years Sun sold ONCR stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Sun As ONCR stock SEC Form 4 insiders trading

Sun has made over 2 trades of the Oncorus stock since 2019, according to the Form 4 filled with the SEC. Most recently Sun bought 173,776 units of ONCR stock worth $2,606,640 on 6 October 2020.

The largest trade Sun's ever made was buying 706,666 units of Oncorus stock on 19 February 2019 worth over $10,599,990. On average, Sun trades about 293,481 units every 198 days since 2019. As of 6 October 2020 Sun still owns at least 2,849,453 units of Oncorus stock.

You can see the complete history of Sun As stock trades at the bottom of the page.

Insiders trading at Oncorus

Over the last 4 years, insiders at Oncorus have traded over $1,276,271 worth of Oncorus stock and bought 2,354,001 units worth $35,555,648 . The most active insiders traders include Ansbert Gadicke, Luke Evnin und James E Deerfield Mgmt Hif,.... On average, Oncorus executives and independent directors trade stock every 34 days with the average trade being worth of $15,538. The most recent stock trade was executed by James E Deerfield Mgmt Hif,... on 28 December 2022, trading 336,235 units of ONCR stock currently worth $87,421.

What does Oncorus do?

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Complete history of Sun As stock trades at TCR2 Therapeutics und Oncorus

Oncorus executives and stock owners

Oncorus executives and other stock owners filed with the SEC include:

• Stephen W. Harbin,
  COO & Chief of Staff
• Dr. Theodore T. Ashburn M.D., Ph.D.,
  Pres, CEO & Director
• Dr. Theodore T. Ashburn,
  Pres, CEO & Director
• Dr. Christophe Queva Ph.D.,
  Chief Scientific Officer & Sr. VP of Research
• Stephen Harbin,
  COO & Chief of Staff
• Dr. Mitchell H. Finer Ph.D.,
  Co-Founder & Non-Exec. Chairman
• Dr. Mitchell H. Finer,
  Co-Founder & Exec. Chairman
• Chris German,
  Controller
• Brian J. Shea,
  Director of Legal Counsel & Corp. Sec.
• Richard J. Wanstall M.B.A.,
  CFO, Chief Accounting Officer & Treasurer
• Dr. John Mayer Goldberg M.D.,
  Sr. VP of Clinical Devel.
• John McCabe M.B.A.,
  CFO, Treasurer & Sec.
• Scott A Canute,
  Director
• Rick Wanstall,
  CFO and Treasurer
• Theodore Ashburn,
  President and CEO
• Christophe Queva,
  CSO and SVP, Research
• James E Deerfield Mgmt Hif,...,
  
• Luke Evnin,
  Director
• Oncology Impact Fund L.P.On...,
  
• Ansbert Gadicke,
  10% owner
• Mitchell H. Finer,
  Director
• Bio Ventures 2014, L.P.Fole...,
  
• Spencer Nam,
  Director
• Sun States Fund, L.P.Mpm As...,
  
• Stephen Harbin,
  COO and Chief of Staff
• John P. Mc Cabe,
  CFO and Treasurer
• Mary Kay Fenton,
  Director
• Eric Rubin,
  Director
• Barbara Yanni,
  Director
• John Mayer Goldberg,
  Chief Medical Officer
• James E Deerfield Mgmt Hif,...,
  
• Douglas Fambrough,
  Director